Hims & Hers adds injectable and oral testosterone treatments for men
Hims & Hers unveils new injectable and oral testosterone options for eligible men, the largest step yet in its men's health line. Shares rose 27 cents.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Hims & Hers Health has rolled out fresh injectable and pill-form testosterone replacement treatments for qualifying men, according to baystreet.ca. The company describes the move as its biggest expansion of men's health offerings since the category debuted last September, adding choices for patients treated by licensed clinicians working with Hims.
The company cites an estimated 20 million U.S. men with low testosterone, a condition that can bring fatigue, muscle loss, reduced libido and erectile problems if untreated. A Hims-commissioned survey of 2,000 American men aged 18 and over suggests more men are discussing these changes openly, with 79% ranking energy above muscle gains. Still, only 45% said they recognize specific low T therapies.
why it matters
This is a company-level development. The release gives no financial figures, and HIMS shares gained just 27 cents to $29.48, so the immediate read-through for the broader market is limited.
tags
instruments
sources
- Hims & Hers Out with New TRT, Shares Break Even — baystreet.ca, 21 October 2026 at 13:51 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗